Valeant Pharmaceuticals International subsidiary Dendreon Pharmaceuticals will be acquired by Sanpower Group.

Valeant will receive a cash consideration of $819.9m for the deal, which will be used to repay a term loan under its senior secured credit facility.

The acquisition is expected to be completed in the first half of 2017.

Indian pharmaceutical company Aurobindo Pharma's subsidiary Agile Pharma has signed a binding agreement with Magnum Capital Partners to acquire Portuguese company Generis Farmaceutica.

Based in the UK, Magnum Capital Partners is a private equity firm.

The acquisition includes a cash purchase consideration of €135m ($142.78m) and is expected to be completed next month.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Aurobindo Pharma aims to expand its business in Portugal through the acquisition.

"Takeda Pharmaceutical Company will acquire Ariad Pharmaceuticals for $5.2bn, which will be funded through existing cash and up to $4bn of new debt."

Takeda Pharmaceutical Company will acquire Ariad Pharmaceuticals for $5.2bn, which will be funded through existing cash and up to $4bn of new debt.

The tender offer represents a purchase consideration of $24 a share, which is a 75% premium over the target company’s closing price on 6 January this year.

The transaction is expected to be completed by the end of next month, as well as enable Takeda Pharma to primarily expand its oncology portfolio.

Takeda Pharma is based in Japan, whereas Ariad Pharma is based in the US.

US-based OmicSoft Corporation has been acquired by Qiagen, a sample and assay technologies provider based in the Netherlands, with the aim of enhancing the latter’s bioinformatics portfolio.

The target company provides bioinformatics, next-generation sequencing, and cancer genomics solutions.